“What if we could replace skin that was severely burned with new, living skin?”
Lead Focus: Severe Burns - Patients who experience severe and extensive, deep partial and full-thickness burn wounds require hospitalization, surgical excision, and skin grafting. During this critical period, patients with severe burns are at high risk of mortality due to the disruption in the skin barrier that contributes to organ failure and often death.
realSKIN™ intends to provide complete wound closure from a single application, by promoting autologous skin regeneration of severe and extensive deep-partial and full-thickness thermal burn wounds requiring hospitalization, surgical excision, and skin grafting for which autografting is clinically indicated.
We have completed our Phase I/II study of patients with severe burns using realSKIN™, a live biotherapeutic skin xenotransplant wound dressing manufactured from living porcine skin
U.S. FDA Designates realSKIN™ as Regenerative Medicine Advanced Therapy - realSKIN™ is the first live cell xenotransplant product to be designated as a Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA). The company's investigational therapy is currently under evaluation in a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of realSKIN™ to provide complete and durable wound closure from a single application, by promoting autologous skin regeneration of severe and extensive deep-partial and full-thickness thermal burn wounds requiring hospitalization, surgical excision, and skin grafting for which autografting is clinically indicated.
Looks, Functions, and Responds Just Like Human Skin